Trial reportClinical and translational gastroenterology2026
Endoscopic Application of Tranexamic Acid and Sucralfate in Upper Gastrointestinal Bleeding: A Randomized Controlled Trial.
Trial report in Clinical and translational gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06421389 (Precise Endoscopic Application of Tranexamic Acid and Sucralfate in Gastrointestinal Bleeding), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Precise Endoscopic Application of Tranexamic Acid and Sucralfate in Gastrointestinal Bleeding: A Randomized Controlled Trial
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
introductionUpper gastrointestinal bleeding (UGIB) is a potentially life-threatening condition. Although standard endoscopic therapies are effective, cases involving tumor-related bleeding or bleeding sites that are challenging to approach remain difficult to manage and are associated with elevated rates of rebleeding. Tranexamic acid (TXA), an antifibrinolytic agent, enhances hemostasis, whereas sucralfate, an antiulcer medication, creates a protective barrier over mucosal injuries. This study evaluated whether the topical application of TXA and sucralfate could reduce the rebleeding rate.
methodsThis single-center, prospective, randomized controlled trial included patients with nonvariceal UGIB who received endoscopic hemostasis. All patients received standard endoscopic therapy. Subsequently, participants were randomly assigned to either standard group or intervention group. Those in the intervention group were treated with an additional endoscopic spray containing 1 g of TXA and 2 g of sucralfate. An additional 1 g of barium sulfate was applied as a radiopaque marker to evaluate the powder retaining time. All participants were monitored for 30 days to evaluate the incidence of rebleeding.
resultsEach group included 30 patients, with comparable baseline characteristics between them. The intervention group demonstrated a significantly lower 28-day rebleeding rate compared with the standard therapy group (10.0% vs 36.7%, P = 0.030).In addition, bleeding-free survival was significantly prolonged in the intervention group ( P = 0.018). Furthermore, the study found that the powder remained at the bleeding site for approximately 8-12 hours. DISCUSSION: Topical application of TXA and sucralfate during endoscopy is safe and potentially effective in reducing 28-day rebleeding for UGIB. This study was registered at ClinicalTrials.gov (NCT06421389).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.